InvestorsHub Logo
Followers 65
Posts 23976
Boards Moderated 0
Alias Born 11/23/2016

Re: WolfofMia post# 437002

Thursday, 10/26/2023 2:21:51 AM

Thursday, October 26, 2023 2:21:51 AM

Post# of 463736
This year all eyes will be on the Rett readout, so in that sense the timing of a P2b/3 AD peer reviewed paper won't make any difference.

So? What difference does it make?


The chances of AA for A2-73 in AD the peer reviewed paper, whenever its released, won't make any difference to either. It may of course reinforce or weaken investors view on the chances.

Pushing ahead with A3-71 in AD seems a good idea whether you are in the WGT or somewhat sceptical camp on A2-73 AA in AD. Hopefully Rett revenue will help Anavex get A3-71 successfully through clinical trials over the next 6 - 10 years.

The longer we wait, the sooner we will get rich!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News